Peptic Ulcers Pipeline Analysis Report 2025

?Peptic ulcers are open sores that develop on the inner lining of the stomach, upper small intestine, or esophagus due to the erosion of the protective mucous layer by gastric acids or a Helicobacter pylori infection. The lifetime prevalence of peptic ulcer disease (PUD) is approximately 5%-10%, with an annual incidence of 0.1%-0.3%. The growth in the drug pipeline is driven by the rising incidence of peptic ulcers, advancements in peptic ulcers drug development, and an increasing focus on combination therapies. Potassium-competitive acid blockers (P-CAB) are actively being used for the treatment. The peptic ulcers pipeline analysis by the publisher highlights ongoing research into innovative therapeutics, such as next-generation proton pump inhibitors and gastroprotective agents, aimed at improving efficacy and patient outcomes.

Report Coverage

The Peptic Ulcers Pipeline Analysis Report by the publisher gives comprehensive insights into peptic ulcers therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Peptic Ulcers. The peptic ulcers report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The peptic ulcers pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition and alignment with peptic ulcers treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to peptic ulcers.

Peptic Ulcers Pipeline Outlook

Peptic ulcers are open sores that develop on the inner lining of the stomach or the upper part of the small intestine. They occur when the protective mucous layer is eroded by stomach acid, often due to Helicobacter pylori infection or prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs). This erosion leads to symptoms like abdominal pain, bloating, and nausea.

Peptic ulcers are treated by eliminating H. pylori infections with a combination of antibiotics and proton pump inhibitors (PPIs), reducing stomach acid with PPIs or histamine (H2) blockers, and protecting the stomach lining with medications like sucralfate. Discontinuing or modifying NSAID use is also recommended when applicable. Lifestyle changes, such as stress management and avoiding irritants like alcohol and smoking, support healing and prevent recurrence. A 2024 review published in JAMA emphasized the importance of eradicating H. pylori to reduce recurrence rates and recommended acid-blocking treatments like proton pump inhibitors as the primary therapy.

Peptic Ulcers Epidemiology

The peptic ulcer disease (PUD) pipeline focuses on innovative treatments to address increasing cases worldwide. The lifelong prevalence in Western countries is 5% to 10%, with an annual incidence of 0.1% to 0.3%. In the United States, PUD affects 1% of the population, leading to around 54,000 hospital admissions annually for bleeding ulcers. Advancements in drug development aim to improve treatment efficacy and patient outcomes.

Peptic Ulcers - Pipeline Therapeutic Assessment

This section of the report covers the analysis of peptic ulcers drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Fusion Proteins
• Monoclonal Antibodies
• Peptides
• Gene Therapies
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Peptic Ulcers Pipeline Assessment Segmentation By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase IV covers a major share of the total peptic ulcers clinical trials. Phase IV, comprising around 52% of the clinical trials, is driving post-marketing research and safety assessments. Phase III, with 24%, focuses on large-scale efficacy trials, ensuring treatment effectiveness, while Phase II has approximately 20%. Advancements in later phases strengthen market growth, improving patient outcomes and treatment accessibility.

Peptic Ulcers Pipeline Assessment Segmentation By Drug Classes

The drug molecule categories covered under the peptic ulcers pipeline analysis include small molecules, fusion proteins, monoclonal antibodies, peptides, gene therapies, and others. The peptic ulcers report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for peptic ulcers.

Antibiotics play a crucial role in treating peptic ulcers caused by Helicobacter pylori infection. A combination therapy with two or three antibiotics, such as amoxicillin, clarithromycin, metronidazole, or tetracycline, alongside a proton pump inhibitor, is commonly prescribed. This approach effectively eradicates the infection, promotes ulcer healing, and reduces the risk of recurrence, particularly in duodenal ulcers.

Key Players in Peptic Ulcers Pipeline

The report for the peptic ulcers pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed peptic ulcers therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in peptic ulcers clinical trials:

• Il-Yang Pharm. Co., Ltd.
• Onconic Therapeutics Inc.
• Shandong New Time Pharmaceutical Co., Ltd.
• PharmaKing
• Daewoong Pharmaceutical Co. Ltd.
• AstraZeneca
• Pfizer
• Takeda Pharmaceuticals

Peptic Ulcers Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for peptic ulcers. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of peptic ulcers drug candidates.

Drug: Misoprostol Oral Tablet

Misoprostol is currently being evaluated in a Phase IV clinical trial sponsored by the Chinese University of Hong Kong. This study aims to assess whether combining misoprostol with lansoprazole is more effective than lansoprazole alone in preventing recurrent bleeding in patients with a history of idiopathic gastroduodenal ulcers. Misoprostol is a synthetic prostaglandin E1 analog approved for preventing and treating gastric ulcers induced by nonsteroidal anti-inflammatory drugs (NSAIDs). It works by protecting the gastrointestinal mucosa and reducing stomach acid secretion.

Drug: Ilaprazole

Ilaprazole, a novel proton pump inhibitor developed by Il-Yang Pharm. Co., Ltd., is currently undergoing a Phase III clinical trial to evaluate its efficacy and safety in preventing NSAID-associated peptic ulcers. The drug is extensively metabolized to ilaprazole sulfone, primarily by the CYP3A enzyme. The study aims to demonstrate Ilaprazole's non-inferiority to an active control by evaluating the proportion of subjects developing peptic ulcers over 24 weeks.

Drug: Vonorasan Fumarate Injection

Vonorasan fumarate injection, sponsored by Shandong New Time Pharmaceutical Co., Ltd., is in a Phase II clinical trial for peptic ulcer bleeding. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) that inhibits gastric acid secretion by reversibly blocking potassium binding to gastric H+/K+ ATPase. This mechanism allows for rapid and potent acid suppression, with a prolonged duration of action compared to traditional proton pump inhibitors (PPIs).?

Key Questions Answered in the Peptic Ulcers Pipeline Analysis Report

• Which companies/institutions are leading the peptic ulcers drug development?
• What is the efficacy and safety profile of peptic ulcers pipeline drugs?
• Which company is leading the peptic ulcers pipeline development activities?
• What is the current peptic ulcers commercial assessment?
• What are the opportunities and challenges present in the peptic ulcers pipeline landscape?
• What is the efficacy and safety profile of peptic ulcers pipeline drugs?
• Which company is conducting major trials for peptic ulcers drugs?
• Which companies/institutions are involved in peptic ulcers collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in peptic ulcers?

Reasons To Buy This Report

The Peptic Ulcers Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for peptic ulcers. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within peptic ulcers pipeline insights.

This product will be delivered within 3-5 business days.